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Fungi are an important but frequently overlooked cause of morbidity and mortality in 10 
humans. Life-threatening fungal infections mainly occur in immunocompromised patients, 11 
and are typically caused by environmental opportunists that take advantage of a weakened 12 
immune system. The filamentous fungus Aspergillus fumigatus is the most important and 13 
well-documented mould pathogen of humans, causing a number of complex respiratory 14 
diseases, including invasive pulmonary aspergillosis, an often fatal disease in patients with 15 
acute leukemia or in immunosuppressed bone marrow or solid organ transplant recipients. 16 
However, non-Aspergillus moulds are increasingly reported as agents of disseminated 17 
diseases, with Fusarium, Scedosporium, Lomentospora and mucormycete species now firmly 18 
established as pathogens of immunosuppressed and immunocompetent individuals. Despite 19 
well-documented risk factors for invasive fungal diseases, and increased awareness of the 20 
risk factors for life-threatening infections, the number of deaths attributable to moulds is 21 
likely to be severely underestimated driven, to a large extent, by the lack of readily 22 
accessible, cheap, and accurate tests that allow detection and differentiation of infecting 23 
species. Early diagnosis is critical to patient survival but, unlike Aspergillus diseases, where a 24 
number of CE-marked or FDA-approved biomarker tests are now available for clinical 25 
diagnosis, similar tests for fusariosis, scedosporiosis and mucormycosis remain 26 
experimental, with detection reliant on insensitive and slow culture of pathogens from 27 
invasive bronchoalveolar lavage fluid, tissue biopsy, or from blood. This review examines the 28 
ecology, epidemiology, and contemporary methods of detection of these mould pathogens, 29 
and the obstacles to diagnostic test development and translation of novel biomarkers to the 30 
clinical setting.   31 
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Abbreviations 36 
AFB (acid-fast bacillus); AIDS (acquired immune deficiency syndrome); ABPA (allergic 37 
bronchopulmonary aspergillosis); ABPM (allergic bronchopulmonary mycosis); AML (acute 38 
myeloid leukaemia); AB (Aspergillus bronchitis); AS (Aspergillus sensitisation); BALf 39 
(bronchoalveolar lavage fluid); CCPA (chronic cavitary pulmonary aspergillosis); CF (cystic 40 
fibrosis); CFPA (chronic fibrosing pulmonary aspergillosis); CGD (chronic granulomatous 41 
disease); CNPA (chronic necrotising pulmonary aspergillosis); CNS (central nervous system); 42 
CPA (chronic pulmonary aspergillosis); COPD (chronic obstructive pulmonary disease); CT 43 
(computed tomography); ELISA (Enzyme-Linked Immunosorbent Assay); EORTC/MSG 44 
(European Organisation for Research and Treatment of Cancer/Mycology Study Group); EPS 45 
(extracellular polysaccharide); FDSC (Fusarium dimerum species complex); FOSC (Fusarium 46 
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oxysporum species complex); FSSC (Fusarium solani species complex); GM (galactomannan); 47 
HSCT (haematopoietic stem-cell transplant); IPA (invasive pulmonary aspergillosis); ISHAM 48 
(International Society for Human and Animal Mycology); LFA (lateral-flow assay); LFD 49 
(lateral-flow device); MRI (magnetic resonance imaging); MAb (monoclonal antibody); MDS 50 
(myelodysplastic syndrome); NPV (negative predictive value); NTM (non-tuberculosis 51 
mycobacteriosis); PCR (polymerase chain reaction); PET (positron emission tomography); 52 
POCT (point-of-care test); PPV (positive predictive value); PSC 53 
(Pseudallescheria/Scedosporium species complex); PTB (pulmonary tuberculosis); SAIA (sub-54 




In 1991, it was estimated that there were 1.5 million species of fungi on the planet 59 
(Hawksworth, 1991). With the advent of high throughput sequencing, that estimate was up-60 
graded to as many as 5.1 million species (Blackwell, 2011). Despite this enormous number, 61 
in which fungi outnumber plants by at least 6 to 1, only ~700 species have been reported as 62 
causing infections in humans (Brown et al., 2012a), while the number that are regularly 63 
reported as disease-causing agents in the clinical setting is limited to an even smaller 64 
number of species. Nevertheless, that handful of species, which includes yeasts, yeast-like 65 
fungi, and moulds, collectively cause enormous but largely unrecognised damage to human 66 
health and well-being in the form of superficial infections of the mucosa, skin and nails 67 
(Schwartz, 2004), deep infections of the bones and joints (Taj-Aldeen et al., 2015), asthma 68 
and allergies (Denning et al., 2014), and life-threatening disseminated infections in already 69 
seriously ill patients, amounting to billions of affected people each year (Brown et al., 70 
2012a,b).  71 
Fungi that cause fatal disseminated infections are typically opportunistic, taking 72 
advantage of immune systems weakened caused by primary immunodeficiences (Lanternier 73 
et al., 2013) or AIDS (Limper et al., 2017), haematological malignancies (Pergam, 2017), or 74 
the use of potent immuno-suppressive therapies that deplete microbial immunity 75 
(Gundacker and Baddley, 2015). The fungi regarded as the most important medically are 76 
Aspergillus, Candida, Coccidioides, Cryptococcus, Histoplasma, Paracoccidioides, 77 
Pneumocystis, and Talaromyces. Only one of these, Aspergillus, is a true filamentous fungus 78 
or mould, the remainder being yeasts, yeast-like, or thermally dimorphic fungi. It is 79 
estimated that Aspergillus diseases, caused principally by the single species Aspergillus 80 
fumigatus, collectively affect around 9 million people worldwide, with a further 10 million 81 
people estimated to be at risk of Aspergillus infection. However, because of under-diagnosis 82 
and under-reporting of Aspergillus diseases, these figures are likely to be under-estimates 83 
(Denning et al., 2013). Also under-diagnosed or under-reported, are the diseases caused by 84 
other mould pathogens (Fusarium spp., species in the Pseudallescheria/Scedosporium 85 
complex (PSC), Lomentospora prolificans, and the mucormycetes comprising, amongst 86 
others, Mucor, Rhizomucor, and Rhizopus spp.), despite their increasing frequency as 87 
infectious etiologies in the ever-expanding populations of immunocompromised and 88 
diabetic patients, and their involvement in polymicrobial diseases following traumatic injury.  89 
The aim of this review is to examine the ecology, epidemiology, and methods of 90 
detection of these under-reported moulds in the context of human disease. It aims to 91 
highlight the paucity of diagnostic tests for these pathogens that, despite repeated calls by 92 
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learned societies, opinion leaders, and action groups for better access to cheap diagnostics, 93 
remain pitifully inadequate, adding to the unacceptably high rates of mordity and mortality 94 
caused by these fungi, and the added financial burden to healthcare providers consequent 95 
of delayed or incorrect diagnosis. The reasons for our repeated failure to develop cheap, 96 
accurate, and user-friendly diagnostic tests are discussed, as are the steps that might be 97 
taken to ‘release the brakes’ on bench-to-bedside translation of diagnostics to the clinical 98 
setting, enabling access to point-of-care tests, particularly in poor and developing countries 99 
that lack access to well-resourced and well-equipped diagnostic facilities.  100 
 101 
Aspergillus species pathogenic to humans 102 
  103 
The genus Aspergillus comprises between 260 and 837 species of ascomycete fungi, making 104 
it one of the most abundant groups of fungi on the planet (Hawksworth, 2011). Despite 105 
their abundance, only a small number of species are known to cause diseases in humans, 106 
with a single anamorphic species Aspergillus fumigatus (teleomorph Neosartorya fischeri) in 107 
the section Fumigati responsible for >80% of recorded infections in humans (Latgé, 1999). 108 
Other well-established species capable of causing infections include A. flavus (section Flavi), 109 
A. terreus (section Terrei), A. niger (section Nigri) and A. nidulans (section Nidulante)(Sugui 110 
et al., 2015), while a number of sibling species of A. fumigatus have emerged as human 111 
pathogens over recent years. These rarer species in the section Fumigati bare morphological 112 
similarities to A. fumigatus, but worryingly also exhibit intrinsic resistance to anti-fungal 113 
drugs (Sugui et al., 2015; Van der Linden et al., 2011), further complicating detection and 114 
treatment with the advent of azole-resistance in clinical strains of A. fumigatus 115 
(Abdolrasouli et al., 2018). Of these emerging species, A. udagawae (Neosartorya 116 
udagawae), A. lentulus, and A. pseudofischeri (Neosartorya pseudofischeri) are the most 117 
frequently reported as causing disease in humans. Notwithstanding these, A. fumigatus 118 
remains the most important pathogen in the Aspergillus genus in terms of prevalence and 119 
capacity to cause disease in humans. It is almost the most important mould pathogen of 120 
humans compared to all other mould species capable of causing life-threatening 121 
disseminated infections. 122 
    123 
Aspergillus diseases  124 
 125 
While Aspergillus spp. have recently emerged as the cause of deep-seated tissue infections 126 
following combat-related injuries in military personnel (Paolino et al., 2012; Warkentien et 127 
al., 2012; Tribble and Rodriguez, 2014), they are best known as opportunistic pathogens 128 
which cause life-threatening infections in immuno-compromised individuals whose impaired 129 
immunity is unable to eliminate the infectious propagules (air-borne spores) inhaled into 130 
the lungs. In patients with defective cell-mediated immunity due to cytotoxic chemotherapy 131 
or T-cell dysfunction due to corticosteroid or other immunosuppressive therapy, Aspergillus 132 
spores germinate to produce invasive hyphae which proliferate, leading to the often-fatal 133 
disseminated disease invasive pulmonary aspergillosis (IPA). These fungi can also cause 134 
allergic and chronic respiratory diseases as a result of an over-zealous host response to 135 
saprotrophic colonisation of the lung following inhalation of air-borne spores. The clinical 136 
consequences of this are most severe in the context of underlying respiratory disorders such 137 
as chronic obstructive pulmonary disease (COPD), post pulmonary tuberculosis (PTB), non-138 
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tuberculosis mycobacteriosis (NTM), bronchiectasis, and cystic fibrosis (CF). The role of 139 
Aspergillus spp. in bronchiectasis in the non-CF lung is less well understood, but Aspergillus 140 
sensitisation and/or allergic bronchopulmonary aspergillosis (ABPA) is a cause and also a 141 
consequence of bronchiectasis (Chotirmall and McElvaney, 2014; Chotirmall and Martin-142 
Gomez, 2018). The sequel to saprotrophic colonisation is infection and the development of 143 
chronic pulmonary aspergillosis (CPA), a slowly progressive lung disease, with poor clinical 144 
outcome (Denning et al., 2011 and 2013; Takazono and Izumikawa, 2018).  145 
The global burden of Aspergillus lung diseases is vast (Bongomin et al., 2017). There are 146 
an estimated 300,000 cases of IPA per year with approximately 10 million at risk annually 147 
(Brown et al., 2012b; Bongomin et al., 2017). The global burden of ABPA in asthma is 148 
approximately 4.8 million, ABPA in cystic fibrosis approximately 6,675, CPA approximately 3 149 
million (including 1.6 million cases post-tuberculosis), with CPA complicating ABPA 150 
approximately 400,000 (Denning et al., 2013). In the United Kingdom, there are estimated 151 
to be around 4,000 cases of IPA each year, 178,000 cases of ABPA in people with asthma, 152 
and 3600 patients with CPA, based on burden estimates post PTB and in sarcoidosis (Pegorie 153 
et al., 2017).     154 
 155 
Invasive Pulmonary Aspergillosis 156 
 157 
A fatality due to disseminated invasive pulmonary aspergillosis was first described in 1953 158 
following autopsy of a patient with agranulocytosis disease (Rankin, 1953). At that time, IPA 159 
was a rare, albeit poorly recognised, disease of immunocompromised patients. It is perhaps 160 
ironic that modern advances in the treatment of haematological malignancies, especially 161 
remission-induction therapy for acute myeloid leukaemia (AML) or myelodysplastic 162 
syndrome (MDS), and the use of highly-effective immune modulating drugs (Kyi et al., 2014; 163 
Reinwald et al., 2016), have led to a dramatic increase in the incidence of IPA in 164 
immunodeficient patients, such that the mortality rate of IPA exceeds 50% in neutropenic 165 
patients, and reaches 90% in haematopoietic stem-cell transplant (HSCT) recipients (Segal, 166 
2009; Kousha et al., 2011). The major risk factors for the disease include neutropenia, HSCT 167 
and solid organ transplantation, high-dose corticosteroids, haematological malignancy, 168 
cytotoxic therapy, advanced AIDS, and chronic granulomatous disease (CGD)(Latgé, 1999; 169 
Dutkiewicz and Hage, 2010).         170 
 171 
Allergic Bronchopulmonary Aspergillosis  172 
 173 
Of the different yeasts and filamentous fungi able to cause allergic bronchopulmonary 174 
mycosis (ABPM) in humans (Chowdary et al., 2014), A. fumigatus and allergic 175 
bronchopulmonary aspergillosis (ABPA) are the most extensively studied. Allergic 176 
bronchopulmonary aspergillosis is one of the most severe Aspergillus-related diseases, with 177 
the potential to progress into pleuropulmonary fibrosis and respiratory failure (Carsin et al., 178 
2017). It occurs almost exclusively in cystic fibrosis or asthmatic patients, and is 179 
characterised by a hypersensitivity reaction to Aspergillus spp., with diverse clinical and 180 







Bronchiectasis is a chronic respiratory disease characterised by progressive and irreversible 187 
dilation of the bronchial lumen, with impaired mucociliary clearance, recurrent infection, 188 
and chronic inflammation. Aspergillus species are the most common filamentous fungi 189 
cultured from respiratory secretions of CF, non-CF, and bronchiectasis patients (Aogáin et 190 
al., 2018; Máiz et al., 2015, 2018). Aspergillus fumigatus is the most frequently recovered 191 
species and the species most likely to cause infections, followed by A. flavus, A. niger and A. 192 
terreus which tend to colonise, rather than infect, the lung (Máiz et al., 2018). These species 193 
also differ in their geographical distributions, with a higher prevalence of A. niger and A. 194 
terreus in Japan, and A. flavus in India and China (Máiz et al., 2018).      195 
 196 
Chronic Pulmonary Aspergillosis  197 
 198 
Chronic pulmonary aspergillosis (CPA) is a semi-invasive disease (Chan et al., 2016), lying 199 
somewhere in between allergic and invasive forms of aspergillosis (Sehgal et al., 2018). It 200 
comprises a number of lung diseases that are long-term sequelae to pulmonary tuberculosis 201 
(PTB), namely Aspergillus nodule, simple pulmonary aspergilloma, chronic cavitary 202 
pulmonary aspergillosis (CCPA; presence of one or more cavities with or without 203 
aspergilloma, accompanied by pulmonary and systemic symptoms), chronic fibrosing 204 
pulmonary aspergillosis (CFPA; cavitation and fibrosis involving two or more lobes), and sub-205 
acute invasive pulmonary aspergillosis (SAIA)(Denning et al., 2016) also called chronic 206 
necrotising pulmonary aspergillosis (CNPA)(Kaymaz et al., 2016) leading to progressive 207 
destruction of the lung (Ohba et al., 2012). CCPA is the most common form of CPA (Denning 208 
et al., 2003), with most cases of CPA occurring in South-East Asia, Western Pacific, and 209 
Africa, where prevalence of PTB is the highest. In high-income settings, COPD appears to be 210 
the most important pre-disposing condition for the disease (Smith and Denning, 2011). 211 
Unlike IPA, CPA occurs in immunocompetent patients after treatment for TB, leading to 212 
weight loss, intense fatigue, severe shortness of breath and life-threatening haemoptysis. 213 
Aspergillus fumigatus is the most frequently identified species in negative acid-fast bacillus 214 
(AFB) sputum smears from sub-Saharan Africans following treatment for PTB. Indeed, CPA is 215 
an important differential diagnosis for what appears to be smear-negative tuberculosis 216 
(Denning et al., 2011). 217 
 218 
Detection of Aspergillus diseases 219 
 220 
Detection of Aspergillus lung diseases remains a significant clinical challenge. Clinical 221 
manifestations of Aspergillus lung infection or colonisation are non-specific, as are 222 
radiological abnormalities seen on X-rays or on computed tomograms of the chest (chest-223 
CT). Despite this, anomalies on a chest-CT are used in some centres to initiate antifungal 224 
drug treatment in at-risk patients. However, the burgeoning costs of antifungal treatments 225 
(Schumock et al., 2016) and prolonged hospitalisation for patients with suspected, but often 226 
unproven, pulmonary mycosis, has turned the spotlight on diagnostics and the need for 227 
improved detection methods that enable the implementation of antifungal stewardship 228 
programmes which have the potential deliver significant savings in antifungal drug 229 
expenditure (Nwankwo et al., 2018).  230 
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Diagnostic-driven approaches to antifungal treatment have been shown to be more 231 
effective than empirical treatment, driving down costs, and improving outcomes for 232 
patients (Barnes, 2013). The emergence of triazole resistance in clinical strains of A. 233 
fumigatus and other Aspergillus spp. (Rivero-Menendez et al., 2016; Abdolrasouli et al., 234 
2018; Zoran et al., 2018), driven by a multiplicity of factors including widespread use of 235 
azole fungicides in agriculture (Fisher et al., 2018; Mortensen et al., 2010; Verweij et al., 236 
2009), anti-fungal prophylaxis (Fisher et al., 2018), evolution of resistance in infecting strains 237 
in the lung during or after long-term (sometimes life-long) therapy with the same antifungal 238 
drug (Howard et al., 2009; Verweij et al., 2016), and sub-therapeutic dosing of patients (van 239 
der Elst et al., 2015), is a serious cause for concern. Up to 12% of Aspergillus infections are 240 
estimated to be resistant to antifungal drugs (Rivero-Menendez et al., 2016), with up to 7% 241 
of Aspergillus strains from stem cell and solid organ transplant patients found to be 242 
resistant (Baddley et al., 2009; Kontoyiannis et al., 2010; Pappas et al., 2010).  243 
Diagnostics has an important part to play in guiding patient treatment, by restricting 244 
the use of antifungal drugs to those that truly need them. It is important to note that a 245 
combination approach to diagnostics is more likely to be effective than a single test 246 
approach, despite pressures to cut healthcare costs. No single test fits all, especially where 247 
an organism such as A. fumigatus is capable of causing a number of different diseases of the 248 
lung. For this reason, abnormalities in a chest-CT that raise the suspicion of a fungal lung 249 
infection in an at-risk patient should be accompanied by complementary biomarker tests 250 
that add additional layers of proof. Biomarker tests such as ‘pan-fungal’ assays for fungal 251 
(1®3)-b-D-glucan, and the Bio-Rad Platelia® ELISA for Aspergillus galactomannan (GM-252 
ELISA) in serum are FDA-approved and are included in the EORTC/MSG and ESCMID-ECMM-253 
ERS guidelines for disease detection (De Pauw et al., 2008; Ullmann et al., 2018), while 254 
others such as the point-of-care Aspergillus lateral-flow device (AspLFD) have been recently 255 
CE-marked and are now available commercially for IPA detection. These assays, and other 256 
commercial or experimental tests currently in development, are discussed in the context of 257 
allergic (ABPA), semi-invasive (CPA), and invasive (IPA) Aspergillus lung diseases. 258 
 259 
Invasive Pulmonary Aspergillosis 260 
 261 
Invasive diagnostic procedures 262 
 263 
Bronchoscopy and culture 264 
 265 
Diagnosis of IPA at the onset of disease is of paramount importance as prognosis worsens 266 
significantly over time. Detection of circulating biomarkers in blood such as Aspergillus 267 
galactomannan, fungal (1®3)-b-D-glucan, and Aspergillus DNA would indicate that the 268 
disease is already well progressed. Early detection of Aspergillus lung infection is only 269 
achievable by using tissue biopsy or bronchoalveolar lavage fluid (BALf) recovered during 270 
invasive bronchoscopy, which allow culture of the pathogen or detection of biomarkers of 271 
infection, respectively. The ‘gold standard’ test for diagnosis of IPA is culture of Aspergillus 272 
from a sterile lung biopsy, with associated necrosis of tissues due to presence of hyphal 273 
elements. There are a number of problems with culture, including the need for invasive 274 
tissue sampling, slow growth or no growth of isolates from cultured material, and difficulties 275 
in differentiating Aspergillus spp. from other agents of hyalohyphomycoses (e.g. other 276 
hyaline septate moulds such as Fusarium and Scedosporium species) in the absence of 277 
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characteristic spore-bearing structures. This leads to lengthy turnaround times, and overall 278 
poor sensitivity of culture-based detection compared to biomarker tests (Prattes et al., 279 
2014). A major benefit of culture is the recovery of isolates for antifungal susceptibility 280 
testing and molecular detection of resistance mutations (Postina et al., 2018), especially 281 
given the increasing prevalence of triazole resistance in A. fumigatus isolates (Abdolrasouli 282 
et al., 2018). 283 
 284 
Biomarker detection in BALf 285 
 286 
Lateral-flow technology 287 
 288 
The advantage of assaying BALf for Aspergillus biomarkers, is that is allows increased 289 
sensitivity and speed of detection compared to culture. The Aspergillus lateral-flow device 290 
(AspLFD), a point-of-care test (POCT) that incorporates a monoclonal antibody (mAb), JF5, 291 
which detects a biomarker of active growth (Thornton, 2008; Thornton, 2014), allows rapid 292 
near-patient diagnosis of IPA, with confirmatory detection of disease using laboratory-based 293 
GM-ELISA, (1®3)-b-D-glucan, or polymerase chain reaction (PCR) tests of BALf samples. 294 
Combination biomarker testing adds considerable power to IPA diagnosis, with a number of 295 
studies demonstrating improvements in diagnostic sensitivity when these assays are used in 296 
combination (Hoenigl et al., 2014; Johnson et al., 2015; Eigl et al., 2017). There have been 297 
numerous studies conducted with the prototype AspLFD test, with two meta-analysis 298 
studies (Pan et al., 2015; Zhang et al., 2019) evaluating its diagnostic performance in 299 
combination with GM-ELISA or (1®3)-b-D-glucan tests. The more recent study by Zhang et 300 
al. (2019), which undertook a meta-analysis of 13 previously-published studies of the 301 
prototype AspLFD, showed that a positive GM-ELISA and a positive (1®3)-b-D-glucan or 302 
AspLFD test provided a confirmatory diagnosis of IPA. 303 
The AspLFD was CE-marked in May 2018 for use with both serum and BALf, with 304 
Mercier et al. (2019a) reporting the performance of the CE-marked test in a retrospective 305 
evaluation of BALf samples from haematology patients across four centres in the 306 
Netherlands and Belgium. In this multicentre study, the CE-marked test had a good 307 
performance for the diagnosis of proven IPA versus controls (no IPA), with a specificity of 308 
86% and sensitivity of 82%. Two follow-up studies (Jenks et al., 2019; Mercier et al., 2019b) 309 
have compared the AspLFD with the newly developed sōna galactomannan lateral-flow 310 
assay (GM-LFA) produced by IMMY. In the study by Jenks et al. (2019), both the AspLFD and 311 
GM-LFA were highly sensitive and specific for probable/proven IPA versus no IPA in patients 312 
with haematological malignancies, with specificities of close to 90% for both the AspLFD and 313 
GM-LFA when read at 15 min, and with 100% sensitivity for the AspLFD when read at 25 314 
min. In patients at risk for IPA but without neutropenia or underlying haematological 315 
malignancy, the GM-LFA and AspLFD tests showed sensitivities ranging from 58% to 69%, 316 
with specificities between 68% and 75% (Jenks et al., 2018). When the two tests were 317 
combined, sensitivity increased to 81% while specificity remained around 60%, making this a 318 
reasonable approach for IPA diagnosis in non-neutropenic patients.  319 
In the study by Mercier et al. (2019b), which retrospectively tested 235 BALf samples of 320 
adult haematology patients from four centres on behalf of the Dutch-Belgian Mycosis Study 321 
Group (DB-MSG), performance of the AspLFD and GM-LFA for proven IPA were similar. In 322 
cases of proven and probable IPA, the tests had identical specificity, but a higher sensitivity 323 
and a better NPV for the GM-LFA. However, a very faint test line is discernible in the GM-324 
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LFA with BALf samples from patients with no IPA, and is also present with the sample 325 
running buffer (i.e. strictly negative tests). This means that a comparator is required in cases 326 
where a weak test line is evident in order to determine whether this is due to non-specific 327 
binding (NSB), or due to an actual but weak line. Because of this ambiguity, a reading card is 328 
included in the IMMY test against which test line intensities are compared. Any test line 329 
considered fainter than a line of semi-quantitative intensity 1 is considered to be negative. 330 
Alternatively, plain running buffer can be used to create a negative control LFA against 331 
which clinical samples can be compared. Any test line more intense than the negative 332 
control can be considered positive. However, this procedure introduces additional 333 
uncertainty, variability, and cost, since a negative control must be included for every sample 334 
run. 335 
While the GM-LFA and AspLFD are both relatively easy to use, the AspLFD is somewhat 336 
simpler, and does not suffer from NSB unlike the IMMY test. For the AspLFD, no sample pre-337 
treatment is required with non-bloody, non-viscous BALf, which can be applied directly to 338 
the test, with results available within 15 minutes. In the case of bloody or viscous BALf, 339 
heating with a buffer (3 minutes) followed by centrifugation (5 minutes) is required, with a 340 
total test time of approximately 25 minutes. For the GM-LFA, all samples must be pre-341 
treated with heating for 6-8 minutes and centrifugation for 5 minutes, bringing the total test 342 
time to roughly 45 minutes. Notwithstanding this, Mercier and co-workers (2019a,b) 343 
conclude that both tests show a good performance for diagnosis of IPA in haematology 344 
patients using BALf. Both tests can be used for fast screening of patients, although 345 
confirmation using an adjunct test such as GM-ELISA, PCR or culture is merited.   346 
 347 
Cytokines  348 
      349 
An important limitation of biomarker tests is that sensitivity may decrease during antifungal 350 
prophylaxis or empirical therapy of patients with haematological malignancies (Eigl et al., 351 
2015; Prattes et al., 2015). To mitigate this loss of test sensitivity, alternative signature 352 
molecules in BALf have recently been explored which might act as adjunct biomarkers of the 353 
disease. Gonçalves et al. (2017) investigated the alveolar cytokine profiles of patients at high 354 
risk of developing IPA. The cytokines IL-1b, IL-6, IL-8, IL-17A, IL-23, and TNF-a were 355 
significantly increased among patients with the disease. However, IL-6, IL-8, and IL-23 best 356 
differentiated between cases of IPA and controls, whereas the remaining cytokines 357 
displayed an inconsistent contribution to discrimination. The cytokine IL-8 was the dominant 358 
discriminator, with alveolar levels of ³904 pg/ml predicting IPA with a sensitivity of 90%, a 359 




Iron is essential for the growth of Aspergillus fumigatus, and targeting its acquisition blocks 364 
infection by the pathogen (Leal et al., 2013). In iron-poor environments such as serum, the 365 
pathogen produces low-molecular-weight siderophores to scavenge ferric iron from the 366 
host (Haas, 2003; Hass et al., 2015). One of these, the extracellular siderophore 367 
triacetylfusarinine C (TAFC), is produced following spore germination, and is detectable in 368 
serum from patients with proven or probable IPA (Carrol et al., 2016). The siderophore is 369 
also detectable in BALf, and an evaluation by Orasch et al. (2017) of BALf samples from 370 
patients with haematological malignancies (of which 73% received antifungal prophylaxis or 371 
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empirical treatment at the time of bronchoscopy) showed that diagnostic sensitivities of the 372 
GM-ELISA and AspLFD tests could be increased when used in combination with TAFC 373 
detection, in line with previous BALf GM-ELISA/AspLFD combination testing (Hoenigl et al., 374 
2014; Prattes et al., 2015).  375 
 376 
Polymerase chain reaction 377 
 378 
Aspergillus polymerase chain reaction (PCR) has been shown for many years to be a 379 
promising diagnostic procedure for IPA detection, especially when combined with other 380 
diagnostic biomarker tests (White et al., 2013; Buchheidt et al., 2017). Despite the 381 
widespread use of ‘in-house’ tests, PCR was not included in the 2008 EORTC/MSG diagnostic 382 
criteria for IPA (De Pauw et al., 2008) due to a lack of assay standardisation and validation.  383 
However, PCR will be included in the latest iteration of the guidelines, following systematic 384 
review of the evidence for its clinical use in comparison with antigen testing (White et al., 385 
2015). The availability of commercial PCR tests has aided assay standardisation (Rath and 386 
Steinmann, 2018), with three PCR assays specifically tailored to Aspergillus detection, and 387 
which have been evaluated using BALf or respiratory samples. The MycAssay Aspergillus® 388 
assay is a real-time PCR which detects A. fumigatus and other Aspergillus spp., with a 389 
sensitivity of 80% to 94.1%, and a specificity of 87.6% to 98.6%, in non-haematology and 390 
mixed patient groups (Torelli et al., 2011; Guinea et al., 2013; Orsi et al., 2015). The 391 
AsperGenius® test comprises two PCR assays, one for the detection and differentiation of 392 
Aspergillus spp. (AsperGenius Species multiplex®), and the other (AsperGenius Resistance 393 
multiplex®) for the detection of four azole resistance markers within the Cyp51A gene of A. 394 
fumigatus (L98H, TR34, T289A, Y121F). The AsperGenius Species multiplex® assay contains a 395 
probe for the A. fumigatus complex (A. fumigatus and the emerging sibling pathogens A. 396 
lentulus, A. udagawae, and A. viridinutans), and a probe for Aspergillus spp. (the A. 397 
fumigatus complex and A. flavus, A. terreus, and A. niger). Using BALf, the AsperGenius® 398 
test has a sensitivity of 68.4% to 84%, and a specificity of 80% to >92% (Chong et al., 2016; 399 
Guegan et al., 2018). In a study of 91 patients with GM-ELISA positive BAlf samples, 79% 400 
were positive for A. fumigatus or Aspergillus spp. DNA, with the azole resistance mutation 401 
TR34/L98H detected in 8 of the cases, and T289A/Y121F mutations in a further 3 cases 402 
(Schauwvlieghe et al., 2017). The MycoGenie® assay detects A. fumigatus and the 403 
TR34/L98H mutation, and has a test sensitivity of 71.1% and specificity of >92% when used 404 
with BALf samples (Guegan et al., 2018). Notwithstanding improvements in PCR 405 
standardisation, the Infectious Diseases Society of America (ISDA) currently recommends 406 
that Aspergillus PCR be used in individual cases if combined with other diagnostic and 407 
clinical data (Misch and Safdar, 2016; Patterson et al., 2016; Lass-Flörl, 2019).  408 
 409 
Semi-invasive and non-invasive diagnostic procedures 410 
 411 
Biomarker detection in serum 412 
 413 
ELISA, PCR, (1®3)-b-D-glucan, and LFD tests 414 
 415 
The literature on the relative specificities and sensititivites of fungal (1®3)-b-D-glucan tests, 416 
Bio-Rad Platelia® GM-ELISA, in-house PCR assays, and prototype AspLFD test, for serum-417 
based diagnosis of Aspergillus diseases is capacious, and has been reported extensively 418 
 10 
elsewhere (Held et al., 2013; White et al., 2013; Pan et al., 2015; Held and Hoenigl, 2017; 419 
Rath and Steinmann, 2018; Ruhnke et al., 2018; Patterson and Donnelly, 2019). 420 
To date, there have been no studies evaluating the diagnostic performance of the CE-421 
marked AspLFD when used with serum samples. However, an ELISA (GP-ELISA) which 422 
employs the same mAb (JF5) used in the AspLFD (and also in the experimental Aspergillus 423 
proximity ligation assay (Mercier et al., 2018)) has recently been developed and CE-marked 424 
by Euroimmun Medizinische Labordiagnostika AG, and its performance compared to the 425 
Platelia® GM-ELISA for IPA diagnosis using serum samples from immunocompromised 426 
patients (Dichtl et al., 2019). While the specificities of the GM-ELISA and GP-ELISA were 99% 427 
and 96%, respectively, both assays demonstrated low sensitivities. When tests were 428 
extended to all sera available in the time frame of 7 days before to 7 days after the day of 429 
proven diagnosis, 47% and 56% of the cases were detected by the GM-ELISA and GP-ELISA, 430 
respectively. The low sensitivities of both tests underline the need for serial tests when 431 
using patient serum.  432 
 433 
Molecular imaging using mAb JF5 and siderophores 434 
 435 
Abnormalities in a chest-CT as diagnostic indicators of IPA (defined as dense, well-436 
delineated, nodular infiltrates with and without ground glass attenuation (the so-called 437 
‘halo sign’))(De Pauw et al., 2008) are not disease-defining, with other pathologies (non-438 
Aspergillus lung infections, and neoplastic and inflammatory processes) giving similar 439 
anomalies. Furthermore, these radiological indicators are transient in neutropenic patients, 440 
or are rare in non-neutropenic patients (Prattes et al., 2014). While magnetic resonance 441 
imaging (MRI) provides unrivalled spatial resolution and soft tissue contrast, and can be 442 
used as a detection aid for Aspergillus cerebral and central nervous system infections 443 
(Starkey et al., 2014; Marzolf et al., 2016), its utility as an imaging modality for lung 444 
infections is limited due to the lack of detectable protons in air-filled spaces and potential 445 
artefacts between air-tissue interfaces.  446 
For these reasons, attempts have been made to improve the accuracy of radiology for 447 
diagnosis of IPA by combining positron emission tomography (PET) with CT and MRI 448 
(Thornton, 2018). The Aspergillus-specific mAb, JF5, when conjugated to the radionuclide 449 
64Cu, has been used in immunoPET/MRI as a disease-specific tracer ([64Cu]NODAGA-JF5), 450 
and allows accurate and sensitive non-invasive detection of A. fumigatus lung infections in 451 
vivo (Rolle et al., 2016; Davies et al., 2017). Furthermore, humanisation of JF5 (Davies et al., 452 
2017) has allowed translation of the imaging technology to the clinic. A first-in-human 453 
clinical trial commenced in 2018, with successful detection of IPA in a neutropenic 454 
haematology patient, corroborated by BALf detection using the AspLFD, GM-ELISA, and 455 
culture (Thornton, pers. comm.). 456 
Alternative approaches to the molecular imaging of IPA include the use of Aspergillus 457 
siderophores in PET. When coupled to 68Ga, a positron emitter with complexing properties 458 
similar to those of Fe(III), the iron-chelating siderophore TAFC showed accumulation in the 459 
lungs of immunosuppressed rats with IPA, with uptake correlating with severity of 460 
Aspergillus infection (Petrik et al., 2010 & 2012a,b). While still at the pre-clinical stage of 461 
development, a [68Ga]TAFC tracer for molecular imaging of Aspergillus lung infections in 462 
vivo, holds enormous diagnostic potential, alongside antibody-guided PET/MR imaging 463 
(immunoPET/MRI), for non-invasive detection of IPA in humans.  464 
 465 
 11 
Biomarker detection in urine 466 
 467 
GM antigenuria  468 
 469 
Evidence for the presence of Aspergillus carbohydrate biomarkers in urine was first shown 470 
in counter-immunodiffusion assays with urine from rabbits experimentally infected with A. 471 
fumigatus (Lehman and Reiss, 1978). Antiserum used in the assay was prepared from an 472 
immunosuppressed and infected rabbit (rather than an animal immunised with an A. 473 
fumigatus antigen preparation), and showed that a carbohydrate antigen was detected in 474 
the urine of the experimentally infected rabbits. Detection of the antigen was not found in 475 
uninfected animals or in animals infected with Candida albicans. While human urinary 476 
antigen was not investigated, and the identity of the carbohydrate was not established, this 477 
early study was the first to demonstrate the excretion of A. fumigatus carbohydrate 478 
antigen(s) into the urine of animals with IPA.  479 
 The identity of a carbohydrate antigen in the urine of experimentally infected 480 
rabbits, and in the urine of patients with IPA, was subsequently demonstrated by Dupont 481 
and co-workers (Dupont et al., 1987). Galactomannan (GM) was detected in animal and 482 
human urine samples using a sandwich ELISA employing rabbit antiserum raised against 483 
purified GM. Using this assay, urinary GM was detectable throughout the course of lethal 484 
aspergillosis in all 16 experimentally infected animals, in concentrations of 24 to 1,900 ng 485 
GM/ml urine, with antigen excretion roughly paralleling the extent of disease. 486 
Galactomannan was detected in the urine of 7 of 13 patients with IPA, with concentrations 487 
of 1 to 83 ng GM/ml urine. A contemporaneous study by Bennett et al. (1987) showed that 488 
within 24 hours after intravenous injection, 35% of galactomannan was excreted into the 489 
urine of immunocompetent rabbits. Galactomannan detection in urine was also investigated 490 
as a means of diagnosing experimental and spontaneous aspergillosis in cattle (Jensen et al., 491 
1993a). An inhibition ELISA using a GM-specific mAb EB-A1 (Stynen et al., 1992), reacted 492 
positively with urine samples from normal cattle, and so could not be used to detect 493 
systemic bovine aspergillosis. The same mAb was used by Haynes et al. (1990) to detect GM 494 
in the urine of neutropenic patients undergoing bone marrow transplantation or remission 495 
induction therapy for leukemia. In immunoblotting studies, EB-A1 showed diffuse staining  496 
(indicative of carbohydrate) in urine samples from patients with IPA, but no staining with 497 
urine from patients without evidence of the disease.  498 
The development of a commercial latex agglutination test for Aspergillus GM (Pastorex 499 
Aspergillus, Sanofi Diagnostics Pasteur, France) using another GM-reactive rat mAb, EB-A2, 500 
also developed by Stynen et al. (1992), enabled standardised testing of GM antigenemia in 501 
the serum of IPA patients as a means of diagnosing IPA. The test was also investigated as a 502 
diagnostic tool for IPA using GM antigenuria in bone marrow transplant recipients (Ansorg 503 
et al., 1994). After modification of the assay for urine testing, it had a detection limit in 504 
native urine of approximately 20 ng GM/ml. Antigen was found in 79 (36.4%) of 217 serial 505 
urine samples, compared to 40 (11.8%) of 340 serum samples. Overall, antigenuria 506 
preceded antigenemia, and was more persistent. The sensitivity, specificity, PPV and NPV of 507 
antigenuria for autopsy-proven aspergillosis and clinically-suspected Aspergillus infection 508 
were 57%, 53%, 31% and 77%, respectively, while those of antigenemia were 43%, 53%, 509 
25% and 71%, respectively. It was therefore concluded that urine testing was more reliable 510 
than serum testing for the detection of Aspergillus GM.     511 
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Refinement of the latex agglutination test led to the development of a quantitative 512 
sandwich ELISA for GM detection in patient serum, and which forms the basis of the 513 
commercial Bio-Rad Platelia® ELISA for GM detection in patient serum and BALf samples. 514 
The ELISA, which detects less than 1ng GM/ml sample, was also investigated as a urine test 515 
for GM in patients with IPA (Stynen et al., 1995). When GM was detected in urine, it was 516 
always lower than in matched serum samples. In addition, GM was always detected earlier 517 
in serum than in urine. The maximal number of days separating patient death and the first 518 
detection of GM in patient serum and urine were ≥39 and ≤12, respectively. Therefore, in 519 
contrast to a previous report (Rogers et al., 1990), it was recommended that serum rather 520 
than urine be used for the detection of GM, because of the later diagnosis obtained with 521 
urine samples.                  522 
Since the pioneering work in the 1990s, there has been limited interest in GM 523 
antigenuria as a detection method for IPA due to reports of its limited utility and high rates 524 
of false positivity, which vary between 8% and 47% (Klont et al., 2004). However, since the 525 
introduction of the AspLFD POCT, which has revolutionised point-of-care testing for the 526 
disease, there has been renewed interest in GM detection in urine, due to its non-invasive 527 
nature and the applicability of lateral-flow technology to urine biomarker testing. Dufresne 528 
et al. (2012) recently reported the development of a new GM-reactive mAb (mAb476), and 529 
demonstrated the feasibility of using the mAb in an immunochromatographic assay for 530 
detection of GM-like antigens in urine. Further development of the assay into a dip-stick 531 
format has demonstrated the potential of the test to detect proven or probable IPA in 532 
patients at high-risk for the disease (patients with haematological malignancy, and 533 
recipients of solid organ or HSCT). Per-patient sensitivity and specificity in the overall cohort 534 
was 80% and 92%, respectively, and the urine assay correlated with serum galactomannan 535 
indices (Marr et al., 2018). While the test uses non-invasive urine samples for GM detection, 536 
the requirement for sample pre-treatment means that it is unlikely to be a point-of-care test 537 
for IPA. Nevertheless, it demonstrates the applicability of lateral-flow technology to urine 538 
testing for Aspergillus diagnostic biomarkers, and for urine-based detection of other fungal 539 
pathogens of humans such as Cryptococcus (Drain et al., 2019) and Histoplasma (Libert et 540 
al., 2018). 541 
 542 
Urine siderophores  543 
 544 
In addition to cell wall carbohydrates such as GM, A. fumigatus and other Aspergillus 545 
species produce proteins that are detectable in urine. These include the iron-scavenging 546 
siderophores TAFC and ferricrocin. In a rat model of experimental aspergillosis, TAFC and 547 
ferricrocin (FC) were quantified in urine and serum with matrix-assisted laser desorption 548 
ionisation (MALDI)(Luptáková et al., 2017). The limits of detection of the ferri-forms of TAFC 549 
and FC in rat serum were 0.28 and 0.36 ng/ml, respectively, while in urine the limits of 550 
detection were 0.02 and 0.03 ng/ml, respectively. The mean concentrations of TAFC and FC 551 
in urine were 0.37 and 0.63 µg/ml, respectively. In a rat model of IPA, ferricrocin and TAFC 552 
detection in urine using mass spectrometry therefore appeared to provide a non-invasive 553 
means of detecting Aspergillus lung infections.           554 
The siderophore TAFC has also been evaluted as a urine biomarker of IPA in humans 555 
using mass spectrometry (Hoenigl et al., 2019). Urine TAFC, normalised to creatinine, was 556 
determined in 44 samples from 24 patients with underlying haematological malignancies 557 
and probable, possible or no IPA, and compared to GM antigenuria using the Bio-Rad 558 
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Platelia® ELISA. Matched blood samples were also tested for GM, and for (1®3)-b-D-glucan 559 
using the Fungitell test. The TAFC/crea index determination in urine samples showed a 560 
promising performance for diagnosis of IPA, with sensitivities and specificities comparable 561 
to those reported for GM in serum and BALf, and superior to GM antigenuria 562 
determinations. Compared to TAFC detection in human BALf and serum samples (Carroll et 563 
al., 2016; Orasch et al., 2017), the diagnostic performance of TAFC levels in urine seems to 564 
be superior, which may be due to accumulation in the bladder as shown in recent animal 565 
models (Petrik et al., 2014 and 2015).          566 
 567 
Allergic Bronchopulmonary Aspergillosis (ABPA) 568 
 569 
Diagnosis of ABPA is extremely difficult, reflected in a number of different diagnostic 570 
definitions of the disease. To unify diagnosis and therapy of ABPA, the International Society 571 
for Human and Animal Mycology (ISHAM) produced consensus-based guidelines in 2013 572 
(Agarwal et al., 2013). Isolation of A. fumigatus from sputum samples can sometimes be 573 
useful, but is not included in the guidelines due to its poor sensitivity and specificity. As with 574 
other Aspergillus lung diseases, consolidation seen in a chest-CT is non-pathognomonic and 575 
may indicate another pulmonary infection such as pulmonary tuberculosis. Nevertheless, 576 
radiographic pulmonary opacities consistent with ABPA (Agarwal et al., 2013) are included 577 
under ‘other criteria’, of which there should be at least two of three present in a patient 578 
with bronchial asthma or cystic fibrosis (the other two being presence of precipitating IgG 579 
antibodies against A. fumigatus in serum, or total eosinophil count >500 cells/µl in steroid 580 
naïve patients). These additional criteria should accompany both of the ‘obligatory criteria’ 581 
which are (1) a positive Type I skin test (immediate cutaneous hypersensitivity to Aspergillus 582 
antigen) or elevated IgE levels against A. fumigatus, and (2) elevated total IgE levels (>1000 583 
IU/ml).   584 
The heavy reliance on serology to include or exclude ABPA has led to efforts to improve 585 
test reproducibility since production of IgG and IgE antibodies to Aspergillus spp. is usually 586 
determined using a crude antigen extract with inherent variability and cross-reactivity with 587 
other fungal antigens (Reed, 1978; Crameri et al., 2009). The cloning of genes that encode 588 
allergenic proteins of A. fumigatus enabled improvements in the reliability of serological 589 
diagnosis of ABPA using recombinant antigens (Crameri et al., 1998a,b; Fricker-Hidalgo et 590 
al., 2010). A recent study by Alghamdi et al. (2019) of CF patients with ABPA, Aspergillus 591 
sensitisation (AS), or Aspergillus bronchitis (AB) showed that patients with ABPA had 592 
significantly greater IgE reactivity to the allergenic proteins Asp f1, f2, f3, and f4 compared 593 
to patients with AS. Patients with AB expressed higher IgG positivity to Asp f1 and Asp f2 594 
compared with those with ABPA. There were very low IgE antibody levels against all 595 
recombinant antigens in AS patients. Asp f1 IgG reactivity in ABPA patients correlated with 596 
positive sputum culture. It was concluded that the use of multiple recombinant allergens 597 
may improve the diagnostic accuracy in CF complicated with ABPA or AB. Furthermore, Asp 598 
f1 reactivity might be a useful marker for guiding antifungal therapy in ABPA. 599 
The role of fungi in bronchiectasis not due to CF is poorly defined. Aogáin et al. (2018) 600 
characterised for the first time the mycobiome in bronchiectasis, assessing its clinical 601 
relevance in two geographically distinct cohorts from the CAMEB study, an international 602 
multicentre cross-sectional Cohort of Asian and Matched European Bronchiectasis patients. 603 
The mycobiome was determined in 238 patients by targeted amplicon shotgun sequencing 604 
of the 18S-28S rRNA internal transcribed spacer regions ITS1 and ITS2. The bronchiectasis 605 
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mycobiome profiles were dominated by A. fumigatus in Singapore/Kula Lumpur, and by A. 606 
terreus in Dundee, the latter associated with exacerbations. High frequences of Aspergillus-607 
associated disease including sensitisation and ABPA were detected. This study showed that 608 
the mycobiome is of clinical relevance in bronchiectasis, and screening for Aspergillus-609 
associated disease should be considered even in apparently stable patients.        610 
 611 
Chronic Pulmonary Aspergillosis (CPA)  612 
 613 
Symptoms of CPA (taken here as CCPA, CFPA, and SAIA/CNPA) are non-specific and, as with 614 
other Aspergillus lung diseases, diagnosis of the disease based on culture of fungi from 615 
respiratory specimens lacks sensitivity, with culture positivity as low as 11.8% (Takazono and 616 
Izumikawa, 2018). Radiological findings on a chest-CT are variable and overlapping and 617 
depend on the state and stage of the disease. Diagnosis of a simple pulmonary aspergilloma 618 
in an immunocompetent individual is based on detection of a single lung cavity with no 619 
progression over at least 3 months of observation, while an Aspergillus nodule is defined by 620 
the presence of one or more nodules without cavitation (Denning et al., 2016; Muldoon et 621 
al., 2016). The diseases CCPA and SAIA share the similar characteristics of one or more 622 
cavities with or without fungal ball, accompanied by radiological progression such as 623 
expanding thick-walled cavities and pericavitary infiltration (Denning et al., 2016). They 624 
differ in that SAIA also involves hyphal invasion of the lung parenchyma (Hope et al., 2005). 625 
This subtle difference creates a diagnostic dilemma, especially when histopathology is 626 
lacking. The time course of radiological progression (CCPA >3 months; SAIA 1-3 months) and 627 
process of cavitary formation (CCPA typically occurs in pre-existing cavities, while SAIA 628 
cavities are formed during Aspergillus infection) are therefore needed for disease 629 
differentiation, but are reliant on serial radiography. The syndrome CFPA is defined by 630 
cavitation and fibrosis involving two or more lobes leading to a major loss of lung function, 631 
and is generally regarded as the end result of untreated CCPA (Denning et al., 2003 and 632 
2016).   633 
Galactomannan-ELISA of serum has limited diagnostic value for CPA detection, with low 634 
sensitivity and specificity even when the threshold index value for test positivity is reduced 635 
from ≥1.5 (the manufacturer’s recommended threshold index value for serodiagnosis of IPA 636 
(Maertens et al., 2007)) to ≥0.5 (Kitasato et al., 2009). Galactomannan-ELISA of BALf showed 637 
relatively higher sensitivity (77.2%) and specificity (77.0%), when the index threshold value 638 
for test positivity was reduced further to ≥0.4 (Izumikawa et al., 2012). In a more recent 639 
study (Salzer et al., 2018), the GM-ELISA was evaluated alongside the AspLFD and levels of 640 
cytokines for diagnosis of CPA (Salzer et al., 2018). Sensitivity and specificity of the GM-641 
ELISA with a cut-off of ≥0.5 was 41% and 100%, respectively. When the cut-off was 642 
increased to ≥1.0, the sensitivity decreased to 30% while specificity remained at 100%. The 643 
AspLFD was positive with only 7% of patients. Therefore, based on test sensitivities, both 644 
the GM-ELISA and AspLFD showed insufficient performance for diagnosing CPA. However, 645 
their high specificities provide high positive predictive values, which may help identify semi-646 
invasive or invasive disease. In this study, the cytokine profiles of CPA patients did not differ 647 
significantly from patients with other respiratory disorders, but showed significantly higher 648 
levels of IFN-g, IL-1b, IL-6, IL-8, and TNF-a compared to healthy controls.  649 
Further evaluation of the AspLFD test using serum and BALf samples from CPA patients 650 
has shown improved diagnostic performance (Takazono et al., 2019). In this study, the 651 
diagnostic performance of the AspLFD was compared to the GM-ELISA and (1®3)-b-D-652 
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glucan tests using samples from patients with SAIA, simple pulmonary aspergilloma, and 653 
respiratory disease controls (PTB, NTM, COPD, interstitial pneumonia, prior lung surgery, 654 
lung cancer, and bacterial infection (pneumonia, lung abscess)). The sensitivity and 655 
specificity of the AspLFD using serum were 62.0% and 67.7%, respectively, while serum GM-656 
ELISA (cut-off index value of ≥1.5) showed a sensitivity of 22% and a specificity of 92.3%, 657 
respectively. Plasma (1®3)-b-D-glucan tests (cut-off value of 19.3 pg/ml), had a sensitivity 658 
of 48% and a specificity of 90.8%, respectively. Using BALf samples, the sensitivity and 659 
specificity of the AspLFD were 66.7% and 69.2%, respectively, while the GM-ELISA (cut-off 660 
index value of ≥0.6) had a sensitivity of 72.7% and specificity of 83.1%. Aspergillus 661 
precipitating antibody had a test sensitivity of 70%.  Given these results, it was concluded 662 
that the performance of the AspLFD serum test was acceptable for the diagnosis of CPA as a 663 
POCT.            664 
As with ABPA, detection of Aspergillus-specific IgG plays and important role in the 665 
diagnosis of CPA (Richardson and Page, 2018). There are a number of Aspergillus-specific 666 
IgG tests available commercially (Page et al., 2016; Takazona et al., 2019). In a study 667 
comparing six of these assays (Page et al., 2016), the automated ImmunoCAP fluoroenzyme 668 
immunoassay and Immunolite ELISA variant (Page et al., 2015) were significantly superior to 669 
the other assays (Dynamiker, Genesis, and Serion) in diagnosing CPA, with identical 670 
specificities (both 96%) and specificities (both 98%). Precipitin testing performed poorly, as 671 
did a recently introduced quantitative serum Aspergillus fumigatus-specific IgM assay (Yao 672 
et al., 2018a). Questions remain concerning the optimum cut-off values for IgG test 673 
positivities, with values provided by manufacturer’s appearing to be sub-optimal for 674 
diagnosis of the disease (Page et al., 2016, 2019; Sehgal et al., 2018). Despite this, it appears 675 
that serial serum testing for Aspergillus-specific IgG may provide a useful means of 676 
monitoring treatment response and outcome since serum IgG levels decrease during 677 
antifungal treatment and resolution (Yao et al., 2018b).  678 
The limitations of the commercial Aspergillus-specific IgG tests are their specificity for 679 
A. fumigatus, their expense, and their reliance on automation. Approximately 40% of CPA 680 
cases are caused by non-fumigatus spp. (e.g. A. niger and A. versicolor), which these tests 681 
would not detect (Tashiro et al., 2011). The cost of the tests and their reliance on 682 
automated procedures makes them unsuitable for resource-limited settings. While most 683 
CPA (and ABPA) patients are diagnosed in high-income countries, prevalence of these 684 
diseases is believed to be higher in low- to middle-income countries (Denning et al., 2011). 685 
Consequently, a test for CPA that requires minimal laboratory equipment, akin to the 686 
AspLFD test for IPA, is needed. This need appears to have been met by a novel anti-687 
Aspergillus antibody LFA manufactured by LDBIO Diagnostics, with other LFAs for Aspergillus 688 
immunoglobulins in development (Richardson and Page, 2018). The LDBIO Diagnostics LFA 689 
or immuno-chromatographic test (ICT) has recently been evaluated in a multicenter 690 
comparison of assays for CPA diagnosis (Piarroux et al., 2019). The sensitivity and specificity 691 
of the ICT were 88.9% and 96.3%, respectively, compared to 93.1% sensitivity and 94.3% 692 
specificity for an anti-Aspergillus IgG immunoblot assay. Since the ICT displays good 693 
diagnostic performance and complies with the ASSURED (Affordable, Sensitive, Specific, 694 
User-friendly, Equipment-free, and Delivered) criteria, it is appropriate for diagnosis of CPA 695 
in resource-limited settings. Marked improvements in IPA detection have been met through 696 
combination diagnostic testing. As advocated previously (Kobayashi and Thornton, 2014), a 697 
similar approach may prove beneficial for CPA diagnosis. A combination of serological and 698 
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biomarker tests such as the LDBIO ICT and OLM AspLFD might allow rapid, simple, cheap, 699 
but accurate diagnosis of the disease.   700 
 701 
Fusarium species pathogenic to humans 702 
 703 
The genus Fusarium comprises plant, human, and animal pathogenic species with 704 
worldwide distribution (Jain et al., 2011; Muraosa et al., 2017). As a group of organisms, 705 
they are a major constraint to food security, not only as pathogen of crop plants, but also as 706 
producer of mycotoxins contaminating the food chain (Thornton and Wills, 2015). In 707 
humans, Fusarium spp. cause a spectrum of diseases including nail infections 708 
(onychomycosis)(Arrese et al., 1996; Westerberg and Voyack, 2013), bone and joint 709 
infections (Koehler et al., 2014), infections of the skin and of burn wounds (Nucci and 710 
Annaissie, 2002; Latenser, 2003; Gurusidappa and Mamatha, 2011; Muhammed et al., 2013; 711 
Nucci et al., 2013; van Diepeningen et al., 2014), mycotic eye infections (fungal 712 
keratitis)(Jurkunas et al., 2009; He et al., 2011), and deep tissue infections following 713 
combat-related blast injury (Paolino et al., 2012; Warkentien et al., 2012; Tribble and 714 
Rodriguez, 2014). Up until the 1980s, most reported Fusarium infections were to the nails 715 
and eyes, or were locally invasive infections. Since then, there has been an increase in the 716 
number of cases of life-threatening disseminated disease (fusariosis) in patients with 717 
haematological malignancies (García-Ruiz et al., 2015), in HIV patients (Esnakula et al., 718 
2013), in patients with diabetes and liver cirrhosis (Chen et al., 2017), in solid organ 719 
transplant recipients (Muhammed et al., 2013; Mohanty and Sahu, 2014), and most 720 
particularly in allogeneic HSCT recipients (Fanci et al., 2013; Scheel et al., 2013; Al-Hatmi et 721 
al., 2016), reflecting their greater immunosuppression and profound and prolonged 722 
neutropenia. Fusariosis is now the second most common mould disease of humans after 723 
aspergillosis (Guarro, 2013), multidrug-resistant and refractory to treatment (Fanci et al., 724 
2013; Al-Hatmi et al., 2016), with poor prognosis (Tortorano et al., 2014), and with mortality 725 
rates reaching 75%.   726 
 At least 70 species of Fusarium are able to cause infections in humans, and are 727 
grouped into species complexes (Guarro, 2013). Most infections in humans are caused by 728 
only four species; F. petroliphilum and F. keratoplasticum in the Fusarium solani species 729 
complex (FSSC)(Short et al., 2013), an unnamed species in the Fusarium dimerum species 730 
complex (FDSC), and a further unnamed species in the Fusarium oxysporum species complex 731 
(FOSC). Members of these species complexes are readily isolated from environmental 732 
samples, including soil and plant material (Thornton and Wills, 2015), air (Scheel et al., 733 
2013), and water systems and plumbing fixtures (Dogget, 2000; Anaissie et al., 2002; Mehl 734 
and Epstein, 2008; Anaissie et al., 2011; Short et al., 2011). Indeed, contaminated water 735 
systems appear to be an important environmental source of pathogenic fusaria in 736 
community-acquired and nosocomial outbreaks of fusariosis, with a recent study showing 737 
that hospital and communal sink biofilms are heavily colonised by pathogenic species in the 738 
FSSC, FDSC, and FOSC complexes (Al-Maqtoofi and Thornton, 2016), and thus a potential 739 






Detection of Fusarium diseases  745 
 746 
Radiology, histology and culture  747 
 748 
In countries with high rates of fungal keratitis, confocal microscopy of the eye has proved 749 
useful in the non-invasive detection of fungal structures (hyphae, pseudo-hyphae, and 750 
yeast-like structures) in the infected cornea (Brasnu et al., 2007). However, direct 751 
microscopy is non-specific, and so is unable to discriminate between the various different 752 
fungi (Aspergillus, Candida, Fusarium) capable of causing mycotic infections of the cornea. 753 
Radiological findings in CT may be useful in raising the suspicion of a Fusarium lung 754 
infection, but are non-specific, with findings including alveolar and interstitial infiltrates, 755 
nodules and cavities that are typical of other mould infections (Marom et al., 2008). In chest 756 
CT, nodules and masses were the most common findings, with a halo sign being absent in 757 
80% of cases.   758 
The ESCMID and ECMM joint guidelines for diagnosis of hyalohyphomycosis strongly 759 
recommend histopathology for the diagnosis of fusariosis (Tortorano et al., 2014). However, 760 
in tissue, the hyphae of Fusarium typically resemble those of Aspergillus, with hyaline and 761 
septate filaments that dichotomise at acute and right angles (Nucci and Anaissie, 2007). 762 
Attempts have been made to improve the accuracy of in situ detection of Fusarium in 763 
tissues, but these remain experimental, relying on immunohistochemical procedures that 764 
employ cross-reactive antisera (Fukuzawa et al., 1995; Kaufman et al., 1997; Saito et al., 765 
1999), or on molecular detection using in-house PCR assays (Salehi et al., 2016). Definitive 766 
diagnosis of invasive Fusarium infections therefore relies on culture of the fungus from skin 767 
biopsies and other infected tissues (sinuses, lungs) or from the blood. Fusariosis is perhaps 768 
unique amongst the invasive mould diseases, in that the pathogens’ infectious propagules 769 
are spread haematogenously, and can be recovered from the bloodstream in up to 82% of 770 
cases (Grossman et al., 2012; Muhammed et al., 2013). In contrast, Aspergillus is rarely 771 
detected in the blood. Haematogenous spread of Fusarium spores accounts for the multiple 772 
necrotic skin lesions that develop in 75-90% of disseminated infections (Van Diepeningen et 773 
al., 2015a), a clinical manifestation uncommon in disseminated aspergillosis. Culture from 774 
tissue and blood samples enables identification of Fusarium based on the crescent or 775 
banana-shaped macroconidia characteristic of this genus. However, identification to species 776 
level, which is essential for guiding clinical management (Muhammed et al., 2011), is 777 
difficult and relies on nucleic acid-based tests of tissue specimens or axenic cultures.    778 
 779 
Nucleic acid tests 780 
 781 
Ribosomal RNA gene sequences, and sequencing of the internal transcribed spacer (ITS) 782 
region, a procedure widely used for the identification of other mould species, is of limited 783 
value for identifying and bar-coding Fusarium species due to the presence of duplicated 784 
divergent alleles in this region. For this reason, molecular identification of clinical isolates 785 
relies on three loci; TEF-1a (translation elongation factor-1a)(García-Ruiz et al., 2015; Zarrin 786 
et al., 2016; Muhammed et al., 2018), RPB1 (the largest subunit of RNA polymerase), and 787 
RPB2 (the second largest subunit of RNA polymerase)(Al-Hatmi et al., 2016). Based on these 788 
loci, DNA sequence databases have been constructed, and can be interrogated at 789 
FUSARIUM-ID (http://isolate.fusariumdb.org/guide.php) and at CBS-KNAW 790 
(http://www.westerdijkinstitute.nl/fusarium/), for the identification of environmental and 791 
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clinical isolates. Using a newly generated Fusarium-specific monoclonal antibody (ED7) that 792 
detects an extracellular antigen (a 200kDa water-soluble carbohydrate), Al-Maqtoofi and 793 
Thornton (2016) were able to track pathogenic fusaria in hospital and communal sink 794 
biofilms, with FSSC sequence type (ST) 1-a, FOSC ST 33, and FDSC ST ET-gr isolates identified 795 
using TEF-1a sequencing of recovered strains. This study demonstrated the specificity of 796 
mAb ED7, which might find use in the detection of Fusarium infections in humans based on 797 
detection of the 200kDa biomarker in patient samples. Multi-locus sequence typing (MLST) 798 
is currently regarded as the most robust method for differentiating Fusarium species 799 
complexes (Wang et al., 2011) or identifying isolates to species level (Tortorano et al., 800 
2014), with TEF-1a and RPB2 employed in many MLST diagnostic regimens (Van 801 
Diepeningen et al., 2015b).  802 
There are currently no nucleic acid-based detection systems CE-marked or FDA-803 
approved for the diagnosis of human fusariosis, but a number of experimental polymerase 804 
chain reaction (PCR) tests have been reported for the detection and quantification of 805 
Fusarium DNA in murine models of fusariosis, and in human tissue specimens (Bernal-806 
Martínez et al., 2012; Muraosa et al., 2014; Salehi et al., 2016). A duplex RT-PCR using two 807 
specific molecular beacon probes targeting a highly conserved region of the rDNA gene was 808 
developed for F. solani and non-Fusarium solani DNA detection, and validated in two mouse 809 
models of invasive infection (Bernal-Martínez et al., 2012). Specificity of the assay was 810 
100%. While sensitivity of the assay in a F. solani infection model was 93.9% for lung tissues 811 
and 86.7% for serum samples, its sensitivity in a F. oxysporum infection model was 87% for 812 
lung tissues and 42.8% for serum samples. A Fusarium genus-specific and FSSC-specific RT-813 
PCR system has also been developed, which targets the 28s ribosomal RNA gene (Muraosa 814 
et al., 2014). To apply the RT-PCR system to the molecular diagnosis of fusariosis, 815 
performance was evaluated using plasma and whole blood samples from a mouse model of 816 
invasive F. solani infection. The sensitivity of the RT-PCR system was found to be 100% in 817 
plasma, but no amplification was detected in whole blood. In a retrospective multicentre 818 
study, Salehi et al. (2016) reported the discrimination of fusariosis, aspergillosis, 819 
mucormycosis, and scedosporiosis in formalin-fixed paraffin-embedded human tissue 820 
specimens using multiple real-time quantitative PCR assays. The qPCR assays, targeting the 821 
ITS2 region of ribosomal DNA using fluorescently labelled primers, was used to identify 822 
clinically important genera and species of Fusarium, Aspergillus, Scedosporium, and 823 
mucormycetes, and the molecular identification compared to results from histological 824 
examination. Fusarium oxysporum and F. solani DNA was amplified from five specimens 825 
from patients initially diagnosed by histopathology as having aspergillosis. This study 826 
demonstrates that histopathological features of moulds may be easily confused in tissue 827 
sections, and that qPCR can be used for the rapid and accurate identification of fungal 828 
pathogens to the genus and species levels directly from FFPE tissues. Despite this, molecular 829 
tests should be used only to supplement conventional laboratory tests (Tortorano et al., 830 
2014).      831 
 832 
Antigen tests 833 
 834 
At present, there are no antigen tests available commercially which are specific for Fusarium 835 
detection. While (1®3)-b-D-glucan detection can be used to diagnose fusariosis both in 836 
animal models (Khan et al., 2008) and in humans, its pan-fungal reactivity means that it 837 
lacks specificity. Disconcertingly, cross-reaction of the Aspergillus GM-ELISA with Fusarium 838 
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spp. has been reported, with roughly half of patients with fusariosis giving a positive test 839 
result with the assay (Tortorano et al., 2012). The reason for this cross-reactivity is 840 
uncertain, but may be due to the presence of the b-1,5-linked Galf moeities recognised by 841 
the GM-reactive mAb EB-A2 being present in polysaccharide antigens from fungi other than 842 
Aspergillus, including Fusarium spp (Tortorano et al., 2012). Certainly, galactomannan has 843 
been found in Fusarium culture supernatants (Tortorano et al., 2012; Wiedemann et al., 844 
2016). The Platelia Candida mannan ELISA has also been reported to cross-react with F. 845 
verticillioides, F. solani and F. oxysporum (Rimek et al., 2003). These findings call into 846 
question the validity of these tests for the specific diagnosis of aspergillosis and candidiasis, 847 
respectively. Despite this, the GM-ELISA has been evaluated in humans as a means of 848 
diagnosing fusariosis and as a monitoring tool for treatment response (Nucci et al., 2014), 849 
but there is little obvious legitimacy for using this assay for fusariosis detection in the clinical 850 
setting given the similar patient groups susceptible to candidiasis, aspergillosis and 851 
fusariosis.  852 
   853 
Pseudallescheria/Scedosporium species complex and Lomentospora 854 
prolificans 855 
 856 
Previously, Pseudallescheria boydii was considered synonymous with Pseudallescheria 857 
angusta, Pseudallescheria ellipsoidea, and Pseudallescheria fusoidea (Rainer et al., 2000), 858 
with a subsequent taxonomic study suggesting that P. boydii is a complex comprising six 859 
species (P. boydii, P. angusta, P. ellipsoidea, P. fusoidea, P. minutispora, and Scedosporium 860 
aurantiacum)(Gilgado et al., 2005). Scedosporium apiospermum along with Graphium spp. 861 
(G. capitatum, G. eumorphum, and G. penicillioides) were considered to be synanomorphs 862 
of P. boydii (Rainer et al., 2006), with S. apiospermum then shown to be a species distinct 863 
from P. boydii (Gilgado et al., 2008), challenging previous doctrine that this fungus was the 864 
asexual or anamorphic state of P. boydii.  Currently, Pseudallescheria and Scedosporium are 865 
regarded as a composite of species, the Pseudallescheria/Scedosporium complex (PSC) 866 
(Luplertlop, 2018), with the genus Scedosporium now comprising S. aurantiacum, S. 867 
desertorum, S. minutisporum, S. cereisporum, and S. dehoogii, in addition to the S. 868 
apiospermum complex consisting of S. angustum, S. apiospermum, S. boydii, S. ellipsoidea, 869 
and S. fusoideum (Ramirez-Garcia et al., 2018). Prior to the advent of molecular taxonomy, 870 
the dematiaceous fungus Scedosporium prolificans (formerly S. inflatum) was believed to be 871 
a member of the genus Scedosporium, but has since been shown to be unrelated to 872 
Scedosporium, and has been re-classified as Lomentospora prolificans (Hennebert and Desai, 873 
1974) with the genus Lomentospora being re-instated for this species (Lackner et al., 2014).     874 
The species S. apiospermum, S. aurantiacum, and S. boydii are pathogenic to humans, 875 
causing eumycetoma, localised cutaneous infections, muscle, joint and bone infections, and 876 
fatal disseminated infections (Cortez et al., 2008; Taylor et al., 2014; Kondo et al., 2018; 877 
Ramirez-Garcia et al., 2018), and are consequently the most studied species in the genus. 878 
These fungi are soil saprotrophs that appear to have a proclivity for habitats impacted by 879 
human activity (Kalteis et al., 2009; Rougeron et al., 2015). However, the evidence for this 880 
association is questionable, since these organisms are also readily isolated from habitats 881 
such as brackish waters and estuarine muds (Thornton, 2009). Notwithstanding this, the 882 
numerous reports of these fungi as agents of disease in near-drowning events and following 883 
natural disasters such as tsunamis due to aspiration of soil-laden water (Garzoni et al., 2005; 884 
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Leroy and Smismans, 2007; Linscott, 2007; Nakamura et al., 2011, 2013; Angelina et al., 885 
2013; Nakamura et al., 2013), demonstrates their abundance in the natural environment, 886 
and their ability to cause life-threatening central nervous system (CNS) and cerebral 887 
infections following traumatic implant of infectious propagules in the lungs (Ramirez-Garcia 888 
et al., 2017). Less is known about the ecology of Lomentospora prolificans, but it is a soil- 889 
and compost-borne fungus (Hennebert and Desai, 1974; Grantina-Ievina et al., 2013), and is 890 
present, alongside members of the PSC, in estuarine muds (Thornton et al., 2015). 891 
Pathogens in the PSC complex and L. prolificans are persistent colonisers of the lungs of 892 
cystic fibrosis (CF) patients, and are the second most frequent moulds after A. fumigatus in 893 
the sputum of CF patients and those with underlying respiratory diseases (Cimon et al., 894 
2000; Cooley et al., 2007; Blyth et al., 2010a,b; Sedlacek et al., 2015; Schwarz et al., 2015; 895 
Schwarz et al., 2017; Tomazin and Matos, 2017; Bouchara et al., 2018; Schwarz et al., 2018). 896 
While chronic airway colonisation of the lung by these fungi can lead to fatal outcomes in CF 897 
patients (Borghi et al., 2010), the role of these fungi in CF exacerbation, other than causing 898 
acute obstruction (Padoan et al., 2016), is not fully understood. Nothwithstanding this, a 899 
trait common to all strains isolated from the CF lung is their high resistance to antifungal 900 
drugs, with L. prolificans demonstrating multi-drug resistance (Borghi et al., 2010; Sedlacek 901 
et al., 2015), and successful treatment of lung infections requiring triple antifungal drug 902 
regimes in several cases (Schwarz et al., 2018). Important risk factors for fatal disseminated 903 
infections (scedosporiosis and lomentosporiosis) include neutropenia and haematological 904 
malignancy (Maertens et al., 2000; Rodriguez-Tudela et al., 2009; Song et al., 2009), 905 
advanced AIDS (Tammer et al., 2011), chronic granulomatous disease (Santos et al., 2000), 906 
allogeneic stem cell transplantation (Tamaki et al., 2016), and solid organ transplantation 907 
(Husain et al., 2005). Malignancy, fungemia, central nervous system (CNS) and lung 908 
involvement are prognostic factors predicting worse outcome for scedosporiosis and 909 
lomentosporiosis (Seidel et al., 2019). Disseminated infections following lung 910 
transplantation are particularly problematic (Vagefi et al., 2005; Morio et al., 2010; Rolfe et 911 
al., 2013), with a S. apiospermum and L. prolificans mixed disseminated infection reported 912 
recently (Balandin et al., 2016).  913 
 914 
Detection of Scedosporium and Lomentospora diseases 915 
 916 
Radiology, histology and culture  917 
 918 
Scedosporium and Lomentospora infections are often clinically indistinguishable from other 919 
invasive mould infections, with radiology based on chest CT providing little diagnostic worth 920 
due to non-specific indicators of fungal lung infection (Dabén et al., 2008; Holmes et al., 921 
2013; Nakamura et al., 2013; Schwarz et al., 2015). In contrast, brain MRI is an important 922 
diagnostic modality for detecting disseminated CNS infections in immunosuppressed stem 923 
cell and solid organ transplant recipients, and in victims of near-drowning, particularly in 924 
cases where antifungal treatment fails to resolve disease, or where a clear spreading focus 925 
is absent (Morio et al., 2010; Bhuta et al., 2012; Holmes et al., 2013; Nakamura et al., 2013; 926 
Sharma and Singh, 2015; Tamaki et al., 2016; Ramirez-Garcia et al., 2018).    927 
Histopathological examination of biopsy material has limited diagnostic utility as it is 928 
difficult to distinguish Scedosporium/Lomentospora-infected tissues from those infected 929 
with other hyaline fungi such as Aspergillus and Fusarium species (Ramirez-Garcia et al., 930 
2018), although the dematiaceous (melanised) hyphae of L. prolificans may provide an 931 
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opportunity for species differentiation. Immunohistological procedures using polyclonal 932 
fluorescent antibodies have attempted to improve the accuracy of in situ detection 933 
(Kaufman et al., 1997), but cross-reaction with antigens from other fungi such as Aspergillus 934 
hamper their usefulness. For these reasons, diagnosis of scedosporiosis and 935 
lomentosporosis relies on the recovery of the etiological agent from clinical specimens and 936 
identification using macroscopic and microscopic features (Ramsperger et al., 2014; Luna-937 
Rodríguez et al., 2019) in vitro. As with Fusarium species, accurate differentiation of species 938 
is critical for guiding clinical management due to variable antifungal susceptibilities (Gilgado 939 
et al., 2006; Cortez et al., 2008; Box et al., 2018). While Scedosporium and Lomentospora 940 
species can be recovered from sterile sites such as blood, bone and tissue biopsy specimens 941 
using standard mycological media, for example Saboraud’s dextrose agar (SDA), their 942 
frequent occurrence in sputum samples of CF patients (Sedlacek et al., 2015; Chen et al., 943 
2017) necessitated the development of selective media that prevent overgrowth by faster 944 
growing Aspergillus, Candida and Fusarium species in polymicrobial clinical samples (Rainer 945 
et al., 2008; Blyth et al., 2010; Hong et al., 2016). One of the most effective media for 946 
selective isolation of Scedosporium species is Scedosporium Selective agar (SceSel+)(Rainer 947 
et al., 2008; Blyth et al., 2010) containing the antifungal agents benomyl and dichloran that 948 
limit the growth of Aspergillus and Candida. Scedosporium species and L. prolificans can 949 
then be further differentiated in culture with the inclusion of cycloheximide that is 950 
inhibitory to L. prolificans (Ramsperger et al., 2014).   951 
 952 
Nucleic acid tests 953 
 954 
Speciation of isolates within the Pseudallescheria/Scedosporium complex and their 955 
discrimination from L. prolificans based on microscopic features requires considerable 956 
expertise and can be problematic. For this reason, a number of molecular methods have 957 
been developed for the detection and differentiation of these fungi in axenic culture, 958 
sputum, and tissue samples including multiplex PCR (Harun et al., 2011); repetitive 959 
sequence-based PCR (rep-PCR)(Steinmann et al., 2011); qPCR, loop-mediated isothermal 960 
amplification (LAMP) and PCR-based reverse line blot (PCR-RLB)(Lu et al., 2011a,b); 961 
oligonucleotide arrays (Bouchara et al., 2009); DNA sequencing and restriction fragment 962 
length polymorphisms (RFLP)(Delhaes et al., 2008; Gilgado et al., 2005, 2008), and Rolling 963 
Circle Amplification (RCA)(Lackner et al., 2012). These techniques and their different 964 
capabilities are comprehensively reviewed elsewhere (Ramsperger et al., 2014; Ramirez-965 
Garcia et al., 2018). Despite these myriad methods for pathogen detection and speciation, 966 
no single technique has been universally adopted nor are any commercial tests currently 967 
recommended for this purpose. Current guidelines recommend that nucleic acid-based 968 
assays be used in combination with conventional laboratory tests (Tortorano et al., 2014).       969 
 970 
Proteomics and antigen tests 971 
 972 
Matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-973 
TOF/MS) has been investigated as an alternative strategy for identification of fungi within 974 
the PSC (Coulibaly et al., 2011), and other pathogenic moulds (Santos et al., 2010; Cassagne 975 
et al., 2011; Bader, 2013; Lau et al., 2013). This technique currently lacks the requisite 976 
standardisation needed for clinical acceptability in medical mycology, but it nevertheless 977 
has the potential to replace gene-sequencing methods for mould identification, as it is 978 
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accurate, comparatively inexpensive and relatively quick compared to sequencing methods. 979 
However, it does require robust online reference databases constructed using similar fungal 980 
growth and extraction procedures for interrogation of MS spectra from unknown species. 981 
Commercially available MALDI-TOF/MS identification solutions are apparently inadequate 982 
for Scedosporium/Lomentospora discrimination at present (Ramirez-Garcia et al., 2018).    983 
Mass spectrometry (MS) has also recently used by Thornton et al. (2015) to identify the 984 
antigen bound by a mAb (CA4) specific to L. prolificans. This IgG1 mAb is highly specific, 985 
binding to an intracellular protein from L. prolificans, but not with proteins extracted from 986 
members of the PSC or from other unrelated moulds. CA4-reactive peptides in western 987 
blots of cell extracts following two-dimensional electrophoresis were identified using MS as 988 
fragments of the melanin-biosynthetic enzyme tetrahydroxynaphthalene reductase (4HNR). 989 
This enzyme is one of a number of enzymes involved in DHN-melanin production of 990 
dematiaceous moulds such as L. prolificans (Al-Laaeiby et al., 2016). Confirmation of the CA4 991 
antigen as the enzyme 4HNR was established using genome sequencing and targeted 992 
disruption of the 4HNR-encoding gene. Mutants lacking the gene, and with abnormal 993 
pigmentation (orange-brown spores compared to the black spores of the wild type strain), 994 
were enzyme-deficient and no longer reactive with mAb CA4. 995 
The study of Thornton et al. (2015) further demonstrates the power of hybridoma 996 
technology to develop mAbs specific to pathogenic moulds, but the generation of a species-997 
specific mAb to an intracellular antigen is unusual. The majority of genus or species-specific 998 
mAbs generated against cell extracts from pathogenic yeasts, yeast-like fungi, and moulds, 999 
bind to carbohydrate moieities on extracellular carbohydrate or glycoprotein antigens 1000 
(Thornton et al., 2002; Thornton, 2009; Davies and Thornton, 2014; Al-Maqtoofi and 1001 
Thornton, 2016; Davies et al., 2017; Morad et al., 2018). This is the case of mAbs specific to 1002 
members of the PSC. Thornton (2009) reported the development of IgG1 (clone HG12) and 1003 
IgM (clone GA3) mAbs specific to a heat-stable, water-soluble, 120kDa carbohydrate 1004 
present on the surface of conidia and hyphae of S. apiospermum, S. aurantiacum, and S. 1005 
boydii. The antigen is also readily detectable as an extracellular antigen that is produced in 1006 
abundance during active growth of these pathogens. The mAbs do not react with the 1007 
related fungus S. dehoogii, with L. prolificans, or other unrelated human pathogenic fungi. 1008 
The copious production of the 120kDa antigen and the availability of highly specific mAbs 1009 
for antigen detection, make this an ideal system for the development of a diagnostic test for 1010 
members of the PSC. To this end, we have developed a lateral-flow assay (Sced-LFA) for PSC 1011 
detection that comprises the IgG1 mAb HG12 (Figure 1), and which demonstrates the 1012 
feasibility of developing a POCT for rapid detection of pathogens in the PSC. In addition, we 1013 
have developed a quantitative sandwich ELISA that combines both mAbs HG12 and GA3. 1014 
This ELISA was recently used by Box et al. (2018) to determine the pharmacodynamics of 1015 
voriconazole in in vitro models of invasive pulmonary scedosporiosis. Given the recent CE-1016 
marking and commercial availability of the AspLFD (OLM Diagnostics) and Aspergillus GP-1017 
ELISA (Euroimmun AG) which both employ the Aspergillus-specific mAb JF5 (Thornton, 1018 
2009), the development of complementary qualitative LFA and quantitative ELISA tests for 1019 
the diagnosis of scedosporiosis, based on detection of the 120kDa in human BALf and serum 1020 





Mucormycete species pathogenic to humans 1025 
 1026 
Mucormycetes are thermotolerant, fast-growing saprotrophic moulds of the phylum 1027 
Zygomycota order Mucorales, which are abundant in a wide range of ecological niches 1028 
including soil and compost (Richardson, 2009), food (e.g. cheese where they cause spoilage 1029 
(Hymery et al., 2014)), edible crops where they cause post-harvest storage rots (Saito et al., 1030 
2016), and household dust (Al-Humiany, 2010). The order Mucorales includes species in the 1031 
genus Apophysomyces, Cunninghamella, Lichtheimia, Mucor, Rhizomucor, Rhizopus, and 1032 
Saksenaea, which are separated from the entomophthoromycetes Basiodiobolus and 1033 
Condiobolus, zygomycete fungi that are also capable of causing disease in humans (Binder et 1034 
al., 2014; Ribes et al., 2000). While mucormycetes such as Rhizopus oryzae (syn. Rhizopus 1035 
arrhizus) and Lichtheimia corymbifera can cause allergic reactions in humans (Sircar et al., 1036 
2015; Rognon et al., 2016), it is the ability of these fungi to cause osteoarticular mycosis 1037 
(Taj-Aldeen et al., 2017), and rhino-orbital-cerebral (Arndt et al., 2009; Son et al., 2016), oral 1038 
(Hingad et al., 2012), pulmonary (Hung et al., 2015; Wang et al., 2016; Iqbal et al., 2017), 1039 
gastrointestinal (Adhikari et al., 2019), cutaneous (Li et al., 2013; Arruebarrena et al., 2016; 1040 
Zahoor et al., 2016) or disseminated infections (Walsh et al., 2012) in pre-disposed adult 1041 
and paediatric patients (Däbritz et al., 2011) that is of the greatest concern, with a single 1042 
species, Rhizopus oryzae responsible for >80% of all life-threatening infections (Richardson, 1043 
2009; Richardson and Page, 2018; Raghunath et al., 2019). This fungus and other pathogenic 1044 
Mucorales (predominantly Lichtheimia, Mucor, and Rhizomucor) differ from other 1045 
opportunistic moulds in their ability to infect a broader, more varied population of human 1046 
hosts (Richardson, 2009; Gomes et al., 2011).    1047 
Cutaneous and deep tissue infections typically occur by direct inoculation during 1048 
trauma, such as following combat-related blast injury (Paolino et al., 2012; Warkentien et 1049 
al., 2012; Tribble and Rodriguez, 2014; Kronen et al., 2017), natural disasters (Andresen et 1050 
al., 2005; Fanfair et al., 2012), or traffic accidents (Lelievre et al., 2014), but are also 1051 
reported in patients with diabetes or haematological malignancies (Arnáiz-García et al., 1052 
2009). Reports of disseminated mucormycosis, while rare, are increasing in incidence 1053 
particularly in patients with uncontrolled diabetes, iron overload, and ketoacidosis (Binder 1054 
et al., 2014; Rammaert et al., 2012), and also in patients with haematological malignancies 1055 
and allogeneic stem cell transplants (Petrikkos et al., 2012; Sugui et al., 2011).  1056 
 1057 
Detection of mucormycosis 1058 
 1059 
Radiology, histology and culture 1060 
 1061 
The aggressive and rapid course of mucormycete infections makes early detection critically 1062 
important for the management both of localised cutaneous, deep-seated, and disseminated 1063 
infections (Castrejón-Pérez et al., 2017). This is especially important in the context of their 1064 
intrinsic resistance to short-tailed mould-active azole drugs (voriconazole (VCZ) and 1065 
fluconazole) due to an evolutionary conserved amino acid substitution in the enzyme 1066 
lanosterol 14a-demethylase responsible for ergosterol biosynthesis (Caramalho et al., 1067 
2017). This has led to an increased incidence of breakthrough infections amongst 1068 
immunocompromised and high-risk patients receiving VCZ prophylaxis, with the suggestion 1069 
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that VCZ prophylaxis should be thought of as one of the risk factors for mucormycosis 1070 
(Ustun et al., 2007).  1071 
As with aspergillosis, fusariosis, and scedosporiosis, abnormalities observed in a chest-1072 
CT consistent with angio-invasive mould infections (nodules, halo signs, cavities, wedge-1073 
shaped infiltrates, and pleurar effusions) are not pathognomonic of pulmonary 1074 
mucormycosis, and so can only raise the suspicion of mucormycosis in the context of a 1075 
patient’s clinical history. Despite this, the reversed halo sign in neutropenic patients with 1076 
haematological malignancies appears to have high predictive value for mucormycosis 1077 
(Legouge et al., 2014; Walsh et al., 2014). Computed tomography has also proven useful in 1078 
the differential diagnosis of rhino-orbital-cerebral mucormycosis (ROCM) and bacterial 1079 
orbital cellulitis, where the early symptoms of both diseases are similar (Son et al., 2016). 1080 
However, it is unable to discriminate between ROCM and aspergillosis in cases of invasive 1081 
fungal rhinosinusitis (Arndt et al., 2009). Culture of mucormycetes from biopsy samples 1082 
(Hong and Park, 2017b) is problematic due to the fragile nature of mucormycete hyphae 1083 
that are aseptate or pauci-septate (Skiada et al., 2013). Growth of mucormycetes in culture 1084 
is rapid, but identification to the level of species and even genus requires considerable 1085 
mycological expertise (Ziaee et al., 2016). As with other pathogenic moulds, MALDI-TOF/MS 1086 
can be used to differentiate species once in axenic culture (Cornely et al., 2014; Cassagne et 1087 
al., 2011; De Carolis et al., 2012; Schrodl et al., 2012), but more data are needed to 1088 
authenticate this technique, and the robustness of reference databases needs to be fully 1089 
evaluated.    1090 
In situ detection of mucormycetes in tissue samples relies on the microscopic 1091 
observation of characteristic broad ribbon-like hyphae that can be stained with optical 1092 
brighteners such as calcofluor white or with Grocott-Gomori methamine silver (Lass-Flörl, 1093 
2009; Antonov et al., 2015; Liao et al., 2015). Sputum and BALf samples can also show the 1094 
characteristic broad aseptate hyphae (Glazer et al., 2000), which is a first indicator of 1095 
mucormycosis (Al-Abbadi et al., 1997). However, in one case study, only 25% of sputum or 1096 
BALf samples were positive pre-mortem (Kontoyiannis et al., 2000). Attempts have been 1097 
made to improve the specificity and sensitivity of microscopy by using mucormycete-1098 
reactive antibodies in immunohistochemistry. The production of rabbit hyper-immune 1099 
antisera and mAbs to immuno-dominant intracellular antigens of the Mucorales was 1100 
reported by Jensen et al. (1994, 1996). Jensen et al. (1994) demonstrated that heterologous 1101 
absorption rendered antisera, raised against Rhizopus oryzae somatic antigens, 1102 
monospecific by indirect immunofluorescence, whereas heterologous absorption of 1103 
Lichtheimia corymbifera antiserum did not abolish reactivity with R. oryzae. The reactivity of 1104 
the heterologously absorbed antisera, and a murine IgG1 mAb (1A7B4) raised against L. 1105 
corymbifera, enabled mucormycetes within bovine lesions to be identified by 1106 
immunohistochemistry. In a subsequent study, Jensen et al. (1996) showed that a mAb 1107 
(WSSA-RA-1), raised against water-soluble somatic antigens from R. oryzae, similarly bound 1108 
to intracellular homologous antigens of between 14kDa and 110kDa. The high degree of 1109 
specificity exhibited by mAb WSSA-RA-1 allowed its use in immunohistochemistry to detect 1110 
the pathogen in situ in placenta, lymph node and gastrointestinal tract samples of cows with 1111 
suspected systemic bovine zygomycosis. In a subsequent study (Jensen et al., 1997), the 1112 
same mAb (WSSA-RA-1) was used in immunohistochemistry to impove the sensitivity and 1113 




Nucleic acid tests 1117 
 1118 
Identification of mucoralean fungi in culture based on morphological characteristics is 1119 
notoriously difficult, particularly with strains that fail to sporulate. For this reason, nucleic 1120 
acid-based procedures have been developed that enable discrimination of Mucorales at 1121 
both genus- and species-level, although evidence that identification beyond genus-level aids 1122 
treatment is lacking. Unlike Fusarium, sequencing of the internal transcribed spacer regions 1123 
ITS1 and ITS2 of ribosomal RNA gene (rDNA) has been shown to be a reliable method for 1124 
species differentiation in the mucormycetes (Gade et al., 2017), with ITS sequencing 1125 
recommended by ISHAM as a first-line method of identification (Balajee et al., 2009). 1126 
Numerous in-house molecular assays have been developed for direct detection of 1127 
mucoralean DNA in clinical samples (Skiada et al., 2018), including BALf (Lengerova et al., 1128 
2014), serum (Millon et al., 2016), and biopsy (skin, lung, stomach mediastine, nose, parotid 1129 
gland) samples (Bernal-Martínez et al., 2012). However, their current lack of standardisation 1130 
means that they are only moderately supported in the clinical guidelines for the diagnosis of 1131 
mucormycosis (Cornely et al., 2014; Skiada et al., 2018). Despite this, PCR has proved useful 1132 
in the detection of mucormycete infections, especially in infections that are culture-negative 1133 
(Hammond et al., 2011). Lengerova et al. (2014) used PCR followed by high-resolution melt 1134 
analysis (PCR/HRMA) to detect Rhizopus spp., Rhizomucor pusillus, Lichtheimia corymbifera, 1135 
and Mucor spp. in BALf samples from immunocompromised patients who were at risk of 1136 
invasive fungal disease. Real-time qPCR assays specific to the species identified in the 1137 
PCR/HMRA test were used to validate the test. Of the 99 BALF samples collected from 86 1138 
patients with pulmonary abnormalities, 91% were negative and 9% were positive in the 1139 
PCR/HMRA test, with a sensitivity and specificity 100% and 93%, respectively. By combining 1140 
the postive PCR/HRMA results with positive real-time qPCR results, the specificity was 1141 
increase to 98%. Due to its high NPV of 99%, the PCR/HRMA test is a fast and reliable 1142 
technique for differential diagnosis of pulmonary mucormycosis in immunocompromised 1143 
patients caused by the four most clinically important mucormycetes.  1144 
Because of the difficulty in obtaining fungal DNA from human fluids, the possibility of 1145 
detecting mucormycete DNA in paraffin-embedded and fresh tissues has been investigated 1146 
in both an experimental model of disseminated mucormycosis (Dannaoui et al., 2010), and 1147 
also in humans (Gade et al., 2017). The universal primers ITS1 and ITS2 were used in PCR to 1148 
amplify the ITS1 region from mucormycete DNA in formalin-fixed paraffin-embedded kidney 1149 
and brain tissues from mice infected with one of five species (Rhizopus oryzae, Rhizopus 1150 
microsporus, Lichtheimia corymbifera, Rhizomucor pusillus, and Mucor circinelloides). 1151 
Amplicons were then sequenced for species identification. Using this procedure, 1152 
identification of major mucormycete species from formalin-fixed paraffin-embedded could 1153 
reach 100%, provided sufficient starting material was available for DNA extraction. Gade et 1154 
al. (2017) investigated the utility of a PCR targeting a 200-300 bp region of the extended 28S 1155 
region of rDNA for molecular identification of DNA from mucormycetes and other fungi in 1156 
formalin-fixed paraffin-embedded and fresh tissues. They demonstrated this region could 1157 
be used to identify all genera and some species of clinically relevant mucormycetes. They 1158 
also demonstrated that PCR amplification and direct sequencing of the extended 28S region 1159 
of rDNA was more sensitive compared to targeting the ITS2 region, since they were able to 1160 
detect and identify mucormycetes and other fungal pathogens in tissues from patients with 1161 
histopathological and/or culture evidence of fungal infections that were negative in PCR 1162 
using ITS-specific primers.   1163 
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Antibody and antigen tests 1164 
 1165 
While there are no routine serological tests for diagnosis of disseminated mucormycosis, 1166 
ELISA has been used to study the relationship between antibody levels and exposure to 1167 
Rhizopus microsporus in sawmill workers with allergic alveolitis (Sandven and Eduard, 1992), 1168 
while recombinant antigens have been developed for the serodiagnosis of farmer’s lung 1169 
caused by Lichtheimia corymbifera (Rognon et al., 2016). Detection of disseminated 1170 
mucormycosis is not possible using tests for (1®3)-b-D-glucan since mucormycetes lack this 1171 
carbohydrate in their cell walls (Cornely et al., 2014), but it can be used to rule out IPA, the 1172 
most frequent differential diagnosis, or combined Aspergillus and Mucorales infections 1173 
(Skiada et al., 2013). Early attempts to detect disseminated disease serologically were based 1174 
on immunodiffusion (Jones and Kaufman, 1978), electrophoresis and immunoblotting 1175 
(Wysong and Waldorf, 1987), and ELISA (Kaufman et al., 1989) of homogenate antigens 1176 
challenged with sera from patients with mucormycete infections. However, non-specific 1177 
reactivity with the antigen preparations was observed with sera from patients with 1178 
aspergillosis and candidiasis also, which meant that the tests were unable to generically or 1179 
specifically identify the etiologic agents of mucormycosis.  1180 
The immunological determinant of mucoralean intracellular glycans has been shown to 1181 
comprise linear (1®6)-a-linked mannopyrasonyl residues (Miyazaki et al., 1979), with the 1182 
cell walls of yeast and hyphal phases of mucoralean fungi containing fucomannopeptide and 1183 
mannoprotein (Yamada et al., 1982, 1983). While these antigens have provided useful 1184 
targets for direct visualisation of mucoralean hyphae in tissue samples using 1185 
immunohistochemistry, their intracellular nature means that they have limited applicability 1186 
as circulating biomarkers of mucormycosis in BALf and serum samples. Approaches have 1187 
been used to identify extracellular antigens specific to the Mucorales (Hessian & Smith 1188 
1982), which might circulate in the bloodstream and therefore be suitable targets for 1189 
detection by, for example, ELISA. Extracellular polysaccharides (EPS) of the Mucorales that 1190 
appear, using polyclonal IgG antibodies, to be specific to this group of fungi, have been 1191 
isolated and characterised (De Ruiter et al., 1991; 1992a,b, 1993, 1994; Notermans and 1192 
Soentoro, 1986), and their immunodominant residues shown to comprise 2-O-methyl-D-1193 
mannose (De Ruiter et al., 1994).  1194 
Despite these extensive early studies, and despite our improved understanding of the 1195 
polysaccharide cell wall architecture of mucoralean fungi (Lecointe et al., 2019), no genus- 1196 
or species-specific mAbs are currently available that target immunogenic EPS, and which 1197 
might prove suitable for the development of immunoassays for diagnosis of mucormycosis 1198 
in humans. Notwithstanding this, somatic antigens diagnostic of systemic L. corymbifera 1199 
infections have been detected in the urine of cattle (Jensen et al., 1993b), indicating that 1200 
biomarkers of mucormycosis circulate in the bloodstream and are excreted. This raises the 1201 
possibility of developing a non-invasive test for mucormycosis based on mucormycete 1202 
antigenuria, provided that suitable targets can be identified and specific mAbs can be 1203 
generated. 1204 
 1205 
Conclusions and Future Prospects 1206 
 1207 
One of the main priorities of the Global Action Fund for Fungal Infections (GAFFI) is 1208 
availability and access of cheap and effective diagnostic tests for all, particularly those in 1209 
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poorly-resourced countries. A commendable priority, but one littered with obstacles. 1210 
Technically, as this review has shown, it is possible to develop highly specific and sensitive 1211 
assays for the detection of some of the most problematic of human pathogens, the 1212 
filamentous fungi or moulds. Furthermore, it is possible to demonstrate the clinical utility of 1213 
these tests in retrospective or semi-prospectve studies. However, the vast majority of these 1214 
tests remain at the experimental stage in the laboratory, with little prospect of translation 1215 
to the clinic as commercially-available CE-marked or FDA-approved assays. One of the 1216 
biggest obstacles to bench-to-bedside translation is the escalating costs for the regulatory 1217 
approvals required at each of the different technical and commercial phases of a test’s 1218 
development, and during its registration as an in vitro medical device (IVD).  1219 
As Figure 1 and the accompanying text demonstrates, the generation of an 1220 
immunoassay, a lateral-flow assay (LFA), that encompasses many of the desirable qualities 1221 
of a near-patient point-of-care test for a human pathogenic fungus (short-time to result; 1222 
inexpensive equipment/instrumentation; suitable for use by personnel with limited training; 1223 
minimal number of steps; uncomplicated interpretation (Kozel and Wickes, 2014; Wickes 1224 
and Wiederhold, 2018)) is relatively simple given the availability of a high quality 1225 
monoclonal antibody (in this case a well-characterised mAb that detects a water-soluble, 1226 
heat-stable, carbohydrate antigen specific to pathogens in the 1227 
Pseudallescheria/Scedosporium complex (Thornton, 2009)), and the technical know-how of 1228 
how to apply it to LFA technology. Production of this demonstration test took a month to 1229 
complete, including antibody purification and conjugation, LFA formatting, and 1230 
determination of specificity and analytical sensitivity. The limit of detection of purified 1231 
antigen is 3.75ng/ml (Figure 1), which is well within the level of analytical sensitivity 1232 
required for clinical detection of a circulating antigen in human samples. Despite this, the 1233 
demand for a PSC-specific test is insufficient to warrant further commercial development of 1234 
the Sced-LFA, despite the importance of this group of fungi in human disease.  1235 
To take a test such as the Sced-LFA from the demonstration phase through to 1236 
prototyping and then into test validation and verification with an FDA-approved 1237 
manufacturer, requires investment beyond the capabilities of many diagnostic companies, 1238 
certainly beyond a small to mid-size enterprise (SME), without a cast-iron guarantee of 1239 
financial return and profit within a short period of time post CE-marking or FDA approval. 1240 
This guarantee is unlikely to be met with tests for emerging or rare pathogens such as 1241 
Fusarium, Lomentospora, Scedosporium, or the mucormycetes, especially given the 1242 
investment and time required for CE-marking and FDA approval of an IVD, and subsequent 1243 
integration of a novel test into hospital diagnostic workstreams. With every hospital or 1244 
regional healthcare authority demanding in-house validation of a test’s performance 1245 
compared to its own established diagnostic procedures, it can typically take several years 1246 
before a test is widely accepted, and is purchased in sufficient numbers so as to justify the 1247 
developer’s costs for R&D, manufacture, marketing, sales and distribution of the test. These 1248 
same principles apply to any diagnostic test, whether it be an antigen test such as the Sced-1249 
LFA, or a molecular diagnostic test for fungal DNA (Wickes and Wiederhold, 2018).  1250 
If GAFFI’s desire for cheap and effective diagnostic tests for all is to be met, there needs 1251 
to be a major re-think in the way that we, as a community of medical mycologists, 1252 
diagnosticians, and medical practitioners, work together to better support the diagnostics 1253 
sector to facilitate the development and translation of novel fungal diagnostics to the 1254 
clinical setting. Without this community support, and without much-needed financial 1255 
assistance from government funding agencies who have traditionally paid insufficient 1256 
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attention to human mycoses and their detection, the availability of cheap, easy-to-use, and 1257 
effective diagnostic tests will be limited to those pathogens which infect sufficiently large 1258 
number of individuals, such as Aspergillus, Cryptococcus, and Pneumocystis, to warrant 1259 
diagnostic test development. An exemplar of where community and funding agency support 1260 
worked to the patient’s advantage was the Aspergillus Technology Consortium (AsTeC) for 1261 
aspergillosis clinical laboratory diagnostics. A similar approach needs to be adopted for 1262 
other invasive mould diseases.  1263 
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Figure 1. Demonstration lateral-flow assay (Sced-LFA) for the detection of pathogens within 2375 
the Pseudallescheria/Scedosporium species complex. A. Schematic diagram showing the 2376 
internal workings of the Sced-LFA test. The monoclonal antibody HG12 (Thornton, 2009) is 2377 
immobilized in the test zone (T) on a porous nitrocellulose membrane. Anti-mouse 2378 
immunoglobulin immobilised to the membrane in a separate zone serves as an internal 2379 
control (C). On addition of 100µl of analyte (for example bronchoalveolar lavage) to the 2380 
release pad (1), mAb HG12 which is conjugated to NanoAct cellulose nanobeads (CNB) in 2381 
the release pad (Y-shaped structures with yellow spheres), binds to the diagnostic 120kDa 2382 
antigen (red spheres) and the antibody-CNB/antigen complex then moves along the porous 2383 
membrane by capillary action (2). The same mAb immobilized in the test zone (T) binds to 2384 
the complex (3), resulting in a positive test line. Any mAb-CNB conjugate that migrates 2385 
unbound to the target antigen, binds to the internal control (C) indicating that the assay has 2386 
run correctly. Where the 120kDa diagnostic antigen is present in the analyte, 2 lines appear 2387 
(T and C) indicating infection, but samples that are antigen negative (no infection) result in a 2388 
single control line (C) only. B. Test results using filtrates from an actively growing culture of 2389 
S. apisopermum, and with mAb HG12 conjugated to red CNB particles. Positive tests results 2390 
(T and C both present) are visible for antigen concentrations ≥3.75ng/ml filtrate (the limit of 2391 
detection). The negative control (antigen-negative culture medium) produces a single 2392 
internal control line only. The single-step Sced-LFA test is highly specific, quick (taking only 2393 
10 minutes to perform from addition of sample to interpretation of result), and is stable for 2394 
18 months at room temperature, making it ideal for use in resource-limited settings. The 2395 
image shown in B is courtesy of the Sced-LFA contract manufacturer LateralDx. Scale bar = 2396 
0.5cm. 2397 
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